Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2021-04-23 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天健会计师事务所关于天士力医药集团股份有限公司非经营性资金占用及其他关联资金往来情况的专项审计说明
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审计说明" (Special Audit Explanation) regarding non-operating fund occupation and other related party fund transactions for the year 2020. It includes an audit opinion from a registered accounting firm, references to Chinese regulatory bodies such as the China Securities Regulatory Commission, and detailed financial tables summarizing related party transactions. The document is a standalone audit report focusing on a specific aspect of the company's financials rather than a full annual report or interim report. It contains substantive audit findings and conclusions about compliance and accuracy of the related party fund transactions. Therefore, it fits the category of an Audit Report / Information (AR). The document length (15,000 characters) and content confirm it is not a mere announcement or certification but a full audit report on a specific financial matter.
2021-04-23 Chinese
天士力2020年年度报告
Annual Report Classification · 100% confidence The document is titled "2020 年年度报告" which translates to "2020 Annual Report". It contains detailed financial data, company business overview, management discussion and analysis, risk disclosures, and audited financial statements. The presence of an audit report with an unqualified opinion is mentioned, and the document length is substantial (15,000 characters). The content includes comprehensive financial performance, business operations, governance, and other typical annual report sections. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2020
2021-04-23 Chinese
天士力关于召开2020年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2020 Annual General Meeting (AGM) of the company TianShiLi Pharmaceutical Group Co., Ltd. It includes details such as the date and time of the meeting, voting methods, agenda items including the 2020 annual report, election of directors and supervisors, and instructions for shareholders. The document is primarily an announcement informing shareholders about the AGM and the related procedures, rather than the actual annual report or voting results. The document length is 4169 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2021-04-23 Chinese
辽宁天士力参茸保健品有限公司关于资产转让事宜的资产评估报告
Regulatory Filings Classification · 95% confidence The document text consists almost entirely of placeholders indicating omitted pictures and scanned images, with no actual textual content or financial data present. There are no references to any specific report type, regulatory body, fiscal period, or financial figures. The document length is 6601 characters, but the content is essentially non-informative and does not contain any report or announcement text. Given the absence of substantive content, this document does not represent a financial report, announcement, or any specific filing type. It is best classified as a Regulatory Filing (RNS), which serves as a fallback category for miscellaneous filings that do not fit other specific categories.
2021-04-23 Chinese
天士力独立董事候选人声明-张斌
Board/Management Information Classification · 95% confidence The document is a declaration statement by an independent director candidate, Zhang Bin, confirming qualifications, independence, and compliance with relevant laws and regulations for serving as an independent director of a listed company. It contains no financial data, no report or meeting results, and no regulatory filings or announcements about financial performance or corporate actions. It is a formal statement related to board/management information, specifically about a director candidate's qualifications and declarations. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report but a direct declaration by the candidate.
2021-04-23 Chinese
天士力关于募集资金年度存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the annual usage and management of funds raised by the company through a non-public issuance of shares. It includes specifics on the amount raised, the timing of fund receipt, usage, balance, management policies, and changes in investment projects related to the raised funds. The document also contains tables showing the usage and changes in the raised funds for the year 2020, with detailed financial figures and explanations. The content focuses on the management and use of capital raised, rather than general financial performance or earnings. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is not an announcement of a report but a substantive report itself, with over 6,900 characters and detailed financial data. Therefore, the appropriate classification is CAP.
2021-04-23 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.